To view or add a comment, sign in Eli Lilly and Company Reports Additional Positive Phase 3 Results for Retatrutide Across Multiple Obesity-Related Conditions On June 6, Eli Lilly and Company announced additional positive pivotal Phase 3 results for its investigational GLP-1/GIP/GCG triple receptor agonist, #Retatrutide
If somebody has a tablet that is scalable, thats a good thing because we can help more patients. But for now, the only GLP-1 options are injectables
Henry provides semaglutide as an injection, oral drops, or dissolvable tablets
The discussion also touches on the need for new distribution strategies for pharmaceutical companies and digital health platforms, emphasizing the importance of compliance and legitimate branded drugs
Education, follow-up, dose adjustments, nutrition, and accountability often make the greatest difference. Dr
Start Your Weight Loss Journey Today Understanding whats included in any approach before you start makes it easier to ask the right questions
